drugset / Trial / NCT02217839

Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173

NCT02217839

Phase 1 Completed 42 enrolled Aspireo Pharmaceuticals Limited
RandomizedSingle-groupSingle-blindTreatment

Summary

This multi-ascending dose study is designed to investigate the safety, tolerability, pharmacokinetic and side effect profile of multiple ascending doses of DG3173, in up to 48 healthy volunteers.

Timeline

Start
2012-04
Primary completion
2013-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide
Subject veldoreotide Protein / enzyme biologic

Indications

No indication recorded.